Sym013 is a mixture of six humanized full length monoclonal antibodies targeting EGFR, HER2 and HER3 which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sym015 is a multi targeting mAb mixture program against undisclosed receptor tyrosine kinase target and stromal target which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sym014 belongs to an antibody drug conjugate program against undisclosed receptor tyrosinekKinase target.which is under development by Symphogen for the treatment of leukemia (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

m013 is a mixture of six humanized full length monoclonal antibodies targeting EGFR, HER2 and HER3 which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500115]).

(Press release, NBE Therapeutics, FEB 21, 2014, View Source;titolo=nbe-therapeutics-announces-validation-of-its-smac-technology-for-adc-development [SID:1234503548])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!